Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Sector

Professional, Scientific, and Technical Services

Industry

Research and Development in Biotechnology

www.recursionpharma.com →

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Alerts

News

10x Genomics: Undervalued Amid Consumables-Led Transition

PEO: Energy Income Fund Capitalizing On Resources With Market Outperformances

Dirt Cheap Stocks to Buy With $1,000 Right Now

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Australia's Santos temporarily shuts Darwin LNG plant amid Mideast supply squeeze

European car sales rise modestly in February, Tesla reverses year-long skid

Kulicke & Soffa Launches ASTERION™‑TW: Innovative Ultrasonic System Expands Power Assembly Portfolio

Kulicke & Soffa Expands Memory Solutions Portfolio

Disney Missed Out on Monday's Market Rally. Is It a Red Flag for the Entertainment Giant?

Exclusive: Amazon says AWS's Bahrain region 'disrupted' following drone activity

SK Hynix: to buy EUV scanners for $8 billion from ASML Korea

Alpha Tau Medical: 2026 Is The Breakthrough Year

Gold sinks deeper into bear market territory as sell-off extends

Chewy Is Down 30% in 2026. Is This a Once-in-a-Lifetime Buying Opportunity?

Nearly 10M pounds of frozen fried rice sold at Trader Joe's added to recall: USDA

NovaBay Rebrands To Stablecoin Development Corp In Full Crypto Pivot— Pharma Company's Stock Climbs 19%

Jensen Huang Sees $1 Trillion in Demand: 3 AI Stocks to Buy Now

BYND DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Beyond Meat, Inc. Investors to Secure Counsel Before Important March 24 Deadline in Securities Class Action - BYND

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action – CORT

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages PennyMac Financial Services, Inc. Investors to Inquire About Securities Class Action Investigation - PFSI

About